The DOI matches its Crossref record; 241 of the 241 references it cites were found in a registry or an index.
Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Open accessAbstract
Cisplatin and other platinum-based chemotherapeutic drugs have been used extensively for the treatment of human cancers such as bladder, blood, breast, cervical, esophageal, head and neck, lung, ovarian, testicular cancers, and sarcoma. Cisplatin is commonly administered intravenously as a first-line chemotherapy for patients suffering from various malignancies. Upon absorption into the cancer cell, cisplatin interacts with cellular macromolecules and exerts its cytotoxic effects through a series of biochemical mechanisms by binding to Deoxyribonucleic acid (DNA) and forming intra-strand DNA adducts leading to the inhibition of DNA synthesis and cell growth. Its primary molecular mechanism of action has been associated with the induction of both intrinsic and extrinsic pathways of apoptosis resulting from the production of reactive oxygen species through lipid peroxidation, activation of various signal transduction pathways, induction of p53 signaling and cell cycle arrest, upregulation of pro-apoptotic genes/proteins, and down-regulation of proto-oncogenes and anti-apoptotic genes/proteins. Despite great clinical outcomes, many studies have reported substantial side effects associated with cisplatin monotherapy, while others have shown substantial drug resistance in some cancer patients. Hence, new formulations and several combinational therapies with other drugs have been tested for the purpose of improving the clinical utility of cisplatin. Therefore, this review provides a comprehensive understanding of its molecular mechanisms of action in cancer therapy and discusses the therapeutic approaches to overcome cisplatin resistance and side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–241 of 241
Gibalová, L., Šereš, M., Rusnák, A., Ditte, P., Labudová, M., Uhrík, B., Pastorek, J., Sedlák, J., Breier, A., & Sulová, Z. (2012) · Toxicology in Vitro · doi:10.1016/j.tiv.2012.01.014 · Cited by 62
Chen, X., Bai, X., Hou, X., Gou, X., Wang, Y.-T., Zeng, H., Huang, M., & Jin, J. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430398 · Cited by 62
C‐Jun N‐terminal kinase signalling pathway in response to cisplatin
Yan, D., An, G., & Kuo, M. T. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12908 · Cited by 61
Kates, M. R., Date, A. A., Yoshida, T., Afzal, U., Kanvinde, P. P., Babu, T., Sopko, N. A., Matsui, H., Hahn, N. M., McConkey, D. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1082 · Cited by 60
Hsieh, M., Wang, C.-W., Lin, J., Chuang, Y., Hsi, Y., Lo, Y., Lin, C., & Chen, M. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.12.028 · Cited by 59
Cavaletti, G., Pezzoni, G., Pisano, C., et al. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00091-5 · Cited by 57
Kong, W., Ling, X., Chen, Y., Wu, X., Zhao, Z., Wang, W., Wang, S., Lai, G., & Yu, Z. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4485 · Cited by 56
Stordal, B., & Davey, R. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909788166592 · Cited by 53
Sherif, I. O., & Al-Gayyar, M. M. H. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.02.027 · Cited by 53
Histopathological Study of Human Cisplatin Nephropathy
Tanaka, H., Ishikawa, E., Teshima, S., & Shimizu, E. (1986) · Toxicologic Pathology · doi:10.1177/019262338601400215 · Cited by 52
Sharma, R. B., Gatchie, L., Williams, I. S., Jain, S. K., Vishwakarma, R. A., Chaudhuri, B., & Bharate, S. B. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.11.013 · Cited by 52
Aldawsari, H. M., & Singh, S. (2020) · Nanomaterials · doi:10.3390/nano10030510 · Cited by 52
Bramson, J. L., & Panasci, L. (1993) · PubMed · Cited by 51
Yu, M., Zhang, C., Tang, Z., Tang, X., & Xu, H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.011 · Cited by 51
Yun, J., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., & Kang, W. K. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.015 · Cited by 50
Zhang, Y., Chen, S., Wei, C., Rankin, G. O., Rojanasakul, Y., Ren, N., Ye, X., & Chen, Y. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.11.045 · Cited by 50
Shen, L., Wen, N., Xia, M., ZHANG, Y., LIU, W., Xu, Y., & Sun, L. (2016) · Oncology Letters · doi:10.3892/ol.2016.4278 · Cited by 49
A computational study of cancer hyperthermia based on vascular magnetic nanoconstructs
Nabil, M., & Zunino, P. (2016) · Royal Society Open Science · doi:10.1098/rsos.160287 · Cited by 49
Bassett, E., Vaisman, A., Leeman, K. T., McCall, C. M., Masutani, C., Hanaoka, F., & Chaney, S. G. (2002) · DNA repair · doi:10.1016/s1568-7864(02)00150-7 · Cited by 48
Taguchi, T. (2009) · Oncology · doi:10.1159/000227740 · Cited by 47
Fabrication and Cytotoxicity of Fucoidan-Cisplatin Nanoparticles for Macrophage and Tumor Cells
Hwang, P., Lin, X.-Z., Kuo, K.-L., & Hsu, F. (2017) · Materials · doi:10.3390/ma10030291 · Cited by 47
Time course of cisplatin-induced nephrotoxicity and hepatotoxicity
Pezeshki, Z., Khosravi, A., Nekuei, M., Khoshnood, S., Zandi, E., Eslamian, M., Talebi, A., Emami, S. N.-E.-D., & Nematbakhsh, M. (2017) · Journal of Nephropathology · doi:10.15171/jnp.2017.28 · Cited by 46
Nan, Y. (2019) · Oncology Reports · doi:10.3892/or.2019.7323 · Cited by 46
Distinct effects of the recurrent Mlh1 G67R mutation on MMR functions, cancer, and meiosis
Avdievich, E., Reiß, C., Scherer, S. J., Zhang, Y., Maier, S. M., Jin, B., Hou, H., Rosenwald, A., Riedmiller, H. N., Kucherlapati, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800276105 · Cited by 44
Overcoming tumor resistance to cisplatin through micelle-mediated combination chemotherapy
Zhou, D., Cong, Y., Qi, Y., He, S., Xiong, H., Wu, Y., Xie, Z., Chen, X., Jing, X., & Huang, Y. (2014) · Biomaterials Science · doi:10.1039/c4bm00305e · Cited by 41
Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins
Siegsmund, M. J., Marx, C., Seemann, O., Schummer, B., Steidler, A., Toktomambetova, L., Köhrmann, K.-U., Rassweiler, J. J., & Alken, P. M. (1999) · Urological Research · doi:10.1007/s002400050103 · Cited by 39
Gan, X., Chen, B., Shen, Z., Liu, Y., Li, H., Xie, X., Xu, X.-Q., Li, H., Huang, Z., & Chen, J. (2014) · PubMed Central · Cited by 39
Lee, J., Chae, J.-W., Kim, J. K., Kim, H. J., Chung, J. Y., & Kim, Y. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.015 · Cited by 38
Galán‐Moya, E. M., Hernández‐Losa, J., Luquero, C. I. A., de la Cruz-Morcillo, M. Á., Ramírez‐Castillejo, C., Callejas‐Valera, J. L., Arriaga, A., Fernández, A., y Cajal, S. R., Gutkind, J. S., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23063 · Cited by 38
The hepatoprotective potential of Spirulina and vitamin C supplemention in cisplatin toxicity
Bhattacharyya, S., & Mehta, P. (2011) · Food & Function · doi:10.1039/c1fo10172b · Cited by 38
Ashrafizadeh, M., Ahmadi, Z., Farkhondeh, T., & Samarghandian, S. (2019) · Biological Trace Element Research · doi:10.1007/s12011-019-01980-4 · Cited by 35
Jeen, Y. T., Yoon, S. Y., Shin, S. W., Kim, B. S., Mok, Y. J., Kim, C. S., Hyun, J. H., Kim, J. S., & Kim, Y. H. (2001) · Cancer · Cited by 32
Lee, J. E. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i1.235 · Cited by 31
Liu, Q., Zhu, D., Hao, B., Zhang, Z., & Tian, Y. (2018) · Cellular and Molecular Biology · doi:10.14715/cmb/2018.64.6.4 · Cited by 31
REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells
Wang, W., Sheng, W., Yu, C., Cao, J., Zhou, J., Wu, J., Zhang, H., & Zhang, S. (2015) · Oncology Reports · doi:10.3892/or.2015.4121 · Cited by 28
Rac1 prevents cisplatin‐induced apoptosis through down‐regulation of p38 activation in NIH3T3 cells
Jeong, H. G., Cho, H.-J., Chang, I. Y., Yoon, S. P., Jeon, Y. J., Chung, M.-H., & You, H. J. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02674-1 · Cited by 28
MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal
Fedier, A., Poyet, C., Perucchini, D., Boulikas, T., & Fink, D. A. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200603000-00010 · Cited by 23
Overexpression of CD133 promotes the phosphorylation of Erk in U87MG human glioblastoma cells
Dong, L., Qi, N., Ge, R.-M., Cao, C., Lan, F., & Shen, L. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.08.057 · Cited by 21
Wu, Y., Zhu, Y., Li, S., Zeng, M., Chu, J., Hu, P., Li, J., Guo, Q., Lv, X., & Huang, G. (2017) · Oncology Letters · doi:10.3892/ol.2017.5758 · Cited by 20
Preclinical Assessment of Low Doses of Cisplatin in the Management of Acute Promyelocytic Leukemia
Dasari, S. R. (2015) · International Journal of Cancer Research and Molecular Mechanisms · doi:10.16966/2381-3318.113 · Cited by 18
Self-citationJiang, H., Chen, P., Su, J., Wu, M. J., Qian, H., Wáng, Y., & Li, J. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25792 · Cited by 18
Metadata
- Authors
- Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., & Kumar, S.
- Venue
- Journal of Experimental Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2021-03
- Volume
- Volume 13
- Pages
- 303-328
- ISSN
- 1179-1454 (ISSN-L)
- OpenAlex
- W3137126526
- Cited by
- 384
- References
- 241
- FWCI
- 19.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.